| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 101 | 2025 | 2382 | 10.450 |
Why?
|
| Antineoplastic Agents, Hormonal | 24 | 2021 | 193 | 5.220 |
Why?
|
| Receptors, Estrogen | 36 | 2025 | 401 | 4.830 |
Why?
|
| Aromatase Inhibitors | 18 | 2022 | 78 | 4.020 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2024 | 881 | 2.850 |
Why?
|
| Estrogen Receptor alpha | 11 | 2023 | 151 | 2.690 |
Why?
|
| Neoadjuvant Therapy | 20 | 2024 | 465 | 2.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 1963 | 2.350 |
Why?
|
| Nitriles | 15 | 2024 | 207 | 2.340 |
Why?
|
| Triazoles | 15 | 2024 | 187 | 2.300 |
Why?
|
| Biomarkers, Tumor | 25 | 2024 | 1321 | 2.250 |
Why?
|
| Triple Negative Breast Neoplasms | 9 | 2024 | 218 | 2.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 8 | 2025 | 53 | 2.080 |
Why?
|
| Cyclin-Dependent Kinase 6 | 7 | 2025 | 49 | 2.040 |
Why?
|
| Proteogenomics | 7 | 2022 | 12 | 2.010 |
Why?
|
| Mutation | 27 | 2024 | 4075 | 1.900 |
Why?
|
| Antineoplastic Agents | 17 | 2024 | 2214 | 1.600 |
Why?
|
| Ki-67 Antigen | 9 | 2024 | 117 | 1.400 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2016 | 33 | 1.360 |
Why?
|
| Gene Expression Profiling | 15 | 2021 | 1767 | 1.180 |
Why?
|
| Proteomics | 19 | 2022 | 1188 | 1.180 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2025 | 981 | 1.130 |
Why?
|
| Quinolines | 5 | 2022 | 190 | 1.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2018 | 108 | 0.980 |
Why?
|
| Opioid-Related Disorders | 6 | 2025 | 602 | 0.970 |
Why?
|
| Female | 114 | 2025 | 78844 | 0.960 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 89 | 0.940 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2025 | 934 | 0.900 |
Why?
|
| Humans | 135 | 2025 | 145474 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2022 | 1149 | 0.840 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2020 | 423 | 0.840 |
Why?
|
| Trastuzumab | 5 | 2020 | 118 | 0.830 |
Why?
|
| Postmenopause | 8 | 2024 | 392 | 0.830 |
Why?
|
| Estradiol | 7 | 2016 | 515 | 0.820 |
Why?
|
| Prognosis | 21 | 2022 | 4316 | 0.810 |
Why?
|
| Piperazines | 6 | 2025 | 375 | 0.800 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 1471 | 0.730 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2024 | 127 | 0.720 |
Why?
|
| Pyridines | 6 | 2025 | 609 | 0.710 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 46 | 0.680 |
Why?
|
| Tamoxifen | 8 | 2019 | 191 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 440 | 0.620 |
Why?
|
| Disease-Free Survival | 11 | 2019 | 767 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.600 |
Why?
|
| Estrogens | 3 | 2011 | 367 | 0.590 |
Why?
|
| Heterografts | 7 | 2021 | 143 | 0.580 |
Why?
|
| Cell Line, Tumor | 16 | 2025 | 3542 | 0.580 |
Why?
|
| MutL Proteins | 2 | 2021 | 3 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 1443 | 0.570 |
Why?
|
| Receptors, Progesterone | 9 | 2018 | 243 | 0.560 |
Why?
|
| Gene Fusion | 1 | 2018 | 30 | 0.560 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2018 | 382 | 0.540 |
Why?
|
| HIV Infections | 2 | 2024 | 3193 | 0.530 |
Why?
|
| Middle Aged | 46 | 2025 | 36215 | 0.530 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 27 | 0.520 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 969 | 0.520 |
Why?
|
| Transcriptome | 9 | 2021 | 1038 | 0.510 |
Why?
|
| Molecular Sequence Annotation | 3 | 2016 | 105 | 0.510 |
Why?
|
| Genomics | 9 | 2022 | 825 | 0.510 |
Why?
|
| Cell Proliferation | 9 | 2025 | 2507 | 0.500 |
Why?
|
| Aged | 40 | 2024 | 26153 | 0.490 |
Why?
|
| Gene Amplification | 6 | 2017 | 118 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 58 | 0.480 |
Why?
|
| Aromatase | 1 | 2016 | 35 | 0.480 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2015 | 62 | 0.480 |
Why?
|
| Proteome | 7 | 2020 | 514 | 0.480 |
Why?
|
| Neoplasms | 9 | 2022 | 2906 | 0.470 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 688 | 0.460 |
Why?
|
| Genome, Human | 3 | 2016 | 420 | 0.460 |
Why?
|
| Treatment Outcome | 17 | 2021 | 11772 | 0.440 |
Why?
|
| Mice | 27 | 2025 | 18329 | 0.430 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2016 | 34 | 0.430 |
Why?
|
| Animals | 34 | 2025 | 38030 | 0.430 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 56 | 0.410 |
Why?
|
| Signal Transduction | 17 | 2021 | 5216 | 0.410 |
Why?
|
| Apoptosis | 6 | 2024 | 2440 | 0.400 |
Why?
|
| Survival Analysis | 8 | 2019 | 1374 | 0.400 |
Why?
|
| Pharmaceutical Services, Online | 1 | 2012 | 1 | 0.380 |
Why?
|
| Adult | 37 | 2025 | 40777 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1327 | 0.380 |
Why?
|
| Neurofibromin 1 | 2 | 2025 | 26 | 0.370 |
Why?
|
| Carcinoma | 2 | 2020 | 225 | 0.360 |
Why?
|
| MCF-7 Cells | 6 | 2021 | 133 | 0.350 |
Why?
|
| Ergocalciferols | 1 | 2011 | 14 | 0.340 |
Why?
|
| E2F Transcription Factors | 1 | 2011 | 65 | 0.340 |
Why?
|
| Prescription Drugs | 1 | 2012 | 111 | 0.330 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 82 | 0.320 |
Why?
|
| RNA, Messenger | 3 | 2021 | 2803 | 0.320 |
Why?
|
| Endocrine System | 1 | 2010 | 22 | 0.320 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1266 | 0.310 |
Why?
|
| Musculoskeletal Diseases | 1 | 2011 | 90 | 0.310 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2121 | 0.310 |
Why?
|
| Mice, Nude | 4 | 2021 | 679 | 0.300 |
Why?
|
| Colonic Neoplasms | 3 | 2019 | 257 | 0.300 |
Why?
|
| Androstadienes | 4 | 2017 | 75 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2013 | 459 | 0.290 |
Why?
|
| Mastectomy | 4 | 2015 | 184 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 1505 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 2378 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 777 | 0.280 |
Why?
|
| Protein Kinases | 4 | 2020 | 312 | 0.270 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2017 | 44 | 0.270 |
Why?
|
| Survival Rate | 5 | 2021 | 2090 | 0.270 |
Why?
|
| Internet | 1 | 2012 | 689 | 0.260 |
Why?
|
| Oxycodone | 2 | 2025 | 52 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 439 | 0.260 |
Why?
|
| Disease Models, Animal | 8 | 2023 | 4560 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 63 | 0.250 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 271 | 0.240 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 8333 | 0.240 |
Why?
|
| Analgesics, Opioid | 4 | 2025 | 1149 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1329 | 0.240 |
Why?
|
| Morpholines | 2 | 2018 | 130 | 0.240 |
Why?
|
| Aminopyridines | 2 | 2018 | 129 | 0.240 |
Why?
|
| Paclitaxel | 3 | 2016 | 257 | 0.230 |
Why?
|
| Carboplatin | 2 | 2022 | 162 | 0.220 |
Why?
|
| ROC Curve | 2 | 2017 | 617 | 0.220 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 189 | 0.210 |
Why?
|
| Prescription Drug Misuse | 1 | 2025 | 52 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2021 | 1707 | 0.210 |
Why?
|
| Homologous Recombination | 1 | 2024 | 37 | 0.210 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 56 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 1747 | 0.210 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 246 | 0.210 |
Why?
|
| Needle-Exchange Programs | 1 | 2024 | 15 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 735 | 0.200 |
Why?
|
| Radiation Tolerance | 1 | 2024 | 103 | 0.200 |
Why?
|
| Naloxone | 1 | 2025 | 131 | 0.200 |
Why?
|
| Tramadol | 1 | 2023 | 17 | 0.200 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 407 | 0.200 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 363 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 454 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2016 | 3747 | 0.190 |
Why?
|
| Harm Reduction | 1 | 2024 | 49 | 0.190 |
Why?
|
| Abscess | 1 | 2024 | 77 | 0.190 |
Why?
|
| Abuse-Deterrent Formulations | 1 | 2023 | 3 | 0.190 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 27 | 0.190 |
Why?
|
| Drug Compounding | 1 | 2024 | 107 | 0.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2014 | 595 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1061 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 1716 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 10885 | 0.190 |
Why?
|
| Peptides | 4 | 2016 | 998 | 0.190 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.190 |
Why?
|
| Mass Spectrometry | 5 | 2018 | 730 | 0.190 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 239 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 203 | 0.190 |
Why?
|
| Incidence | 5 | 2023 | 2923 | 0.180 |
Why?
|
| Computational Biology | 4 | 2015 | 669 | 0.180 |
Why?
|
| Health Equity | 1 | 2025 | 133 | 0.180 |
Why?
|
| Purines | 1 | 2023 | 187 | 0.180 |
Why?
|
| Transfection | 2 | 2018 | 926 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 325 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 321 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2020 | 219 | 0.180 |
Why?
|
| Alleles | 2 | 2016 | 894 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 820 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 165 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2015 | 170 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 431 | 0.170 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 53 | 0.170 |
Why?
|
| Transcription Factor AP-1 | 1 | 2020 | 79 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 1419 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2015 | 992 | 0.160 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 15 | 0.160 |
Why?
|
| Basal Ganglia Diseases | 1 | 2020 | 9 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 3 | 2016 | 210 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 886 | 0.150 |
Why?
|
| Buprenorphine | 1 | 2023 | 191 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2018 | 221 | 0.150 |
Why?
|
| Mastectomy, Segmental | 3 | 2015 | 107 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2023 | 728 | 0.150 |
Why?
|
| tau Proteins | 1 | 2020 | 105 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2020 | 6013 | 0.140 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 231 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 228 | 0.140 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 8 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 18 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 534 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 712 | 0.140 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 10 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 198 | 0.140 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 8 | 0.140 |
Why?
|
| Endonucleases | 1 | 2018 | 34 | 0.140 |
Why?
|
| Imidazoles | 2 | 2010 | 247 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 23 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 668 | 0.140 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 372 | 0.140 |
Why?
|
| Thymidine Kinase | 1 | 2017 | 16 | 0.130 |
Why?
|
| Time Factors | 5 | 2016 | 7123 | 0.130 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2017 | 36 | 0.130 |
Why?
|
| Drug Synergism | 2 | 2016 | 354 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 142 | 0.130 |
Why?
|
| Genomic Instability | 2 | 2020 | 67 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2016 | 337 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2020 | 618 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 205 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 925 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 3413 | 0.130 |
Why?
|
| Translocation, Genetic | 2 | 2018 | 119 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 441 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2017 | 25 | 0.130 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 83 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 734 | 0.120 |
Why?
|
| Spiro Compounds | 1 | 2016 | 17 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2015 | 2158 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2017 | 762 | 0.120 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2016 | 4 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 344 | 0.120 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2016 | 49 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 1101 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 67 | 0.120 |
Why?
|
| Proteolysis | 1 | 2017 | 172 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2017 | 572 | 0.120 |
Why?
|
| Clone Cells | 1 | 2016 | 263 | 0.120 |
Why?
|
| SEER Program | 2 | 2014 | 229 | 0.120 |
Why?
|
| Point Mutation | 2 | 2014 | 240 | 0.120 |
Why?
|
| RNA Interference | 3 | 2018 | 475 | 0.120 |
Why?
|
| United States | 7 | 2025 | 16098 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 26 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 534 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 79 | 0.110 |
Why?
|
| Capecitabine | 1 | 2015 | 56 | 0.110 |
Why?
|
| Risk | 2 | 2015 | 919 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 116 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 637 | 0.110 |
Why?
|
| Epitopes | 1 | 2017 | 473 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 96 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 165 | 0.110 |
Why?
|
| Genotype | 3 | 2015 | 1852 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 372 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 425 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5423 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 919 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 81 | 0.110 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 310 | 0.110 |
Why?
|
| Biomarkers | 3 | 2017 | 4295 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2014 | 48 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 977 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1547 | 0.100 |
Why?
|
| Neuregulin-1 | 1 | 2014 | 49 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2017 | 598 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2019 | 337 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2016 | 182 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 630 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2020 | 1891 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2014 | 47 | 0.100 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2013 | 1 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 506 | 0.100 |
Why?
|
| Cold Ischemia | 1 | 2014 | 40 | 0.100 |
Why?
|
| Asphyxia Neonatorum | 1 | 2013 | 21 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 97 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 54 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2013 | 4 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 62 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 181 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2015 | 247 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 442 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 591 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 74 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 259 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 159 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 452 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 2129 | 0.090 |
Why?
|
| Sirolimus | 3 | 2013 | 280 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 146 | 0.090 |
Why?
|
| Young Adult | 9 | 2025 | 14218 | 0.090 |
Why?
|
| Indoles | 1 | 2016 | 507 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2016 | 654 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 394 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 503 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 542 | 0.090 |
Why?
|
| Pain | 2 | 2023 | 789 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 331 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 387 | 0.090 |
Why?
|
| Disease Progression | 2 | 2020 | 2864 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 749 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2016 | 379 | 0.090 |
Why?
|
| Gene Expression | 2 | 2015 | 1476 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2014 | 238 | 0.090 |
Why?
|
| Bone Density | 2 | 2014 | 487 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 266 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2013 | 317 | 0.080 |
Why?
|
| Poison Control Centers | 2 | 2025 | 85 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 1480 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 114 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3623 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 972 | 0.080 |
Why?
|
| Global Health | 1 | 2013 | 403 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 855 | 0.080 |
Why?
|
| Chromatography, Liquid | 3 | 2017 | 450 | 0.080 |
Why?
|
| Mice, Inbred NOD | 3 | 2017 | 613 | 0.080 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 60 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 2028 | 0.080 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 61 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 45 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 68 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 641 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 561 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 48 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 776 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 161 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 205 | 0.070 |
Why?
|
| Missouri | 2 | 2023 | 66 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 3342 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 369 | 0.070 |
Why?
|
| Male | 11 | 2025 | 72842 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 2883 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2016 | 2062 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 102 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5904 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 184 | 0.070 |
Why?
|
| Vitamin D | 1 | 2011 | 403 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 343 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1598 | 0.060 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 24 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2019 | 8057 | 0.060 |
Why?
|
| Trinidad and Tobago | 2 | 2018 | 5 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 217 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 270 | 0.060 |
Why?
|
| Perception | 1 | 2010 | 378 | 0.060 |
Why?
|
| Cell Line | 1 | 2012 | 2823 | 0.060 |
Why?
|
| DNA Repair | 2 | 2020 | 254 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 333 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2020 | 157 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2006 | 21 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 686 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2015 | 2445 | 0.060 |
Why?
|
| Genome | 2 | 2021 | 305 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 1399 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1300 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 666 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 390 | 0.060 |
Why?
|
| Quality of Life | 2 | 2009 | 3204 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 64 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2021 | 635 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1734 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 471 | 0.050 |
Why?
|
| Phenotype | 1 | 2013 | 3155 | 0.050 |
Why?
|
| Calcium | 1 | 2011 | 1190 | 0.050 |
Why?
|
| Algorithms | 3 | 2019 | 1845 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2005 | 85 | 0.050 |
Why?
|
| Rad51 Recombinase | 1 | 2024 | 15 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 133 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 140 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 85 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 68 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 82 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 168 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 530 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 503 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 639 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 782 | 0.050 |
Why?
|
| Oxymorphone | 1 | 2023 | 5 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 425 | 0.050 |
Why?
|
| Phenols | 1 | 2023 | 106 | 0.050 |
Why?
|
| Proteins | 2 | 2021 | 1023 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 345 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 1138 | 0.040 |
Why?
|
| Staurosporine | 2 | 2012 | 22 | 0.040 |
Why?
|
| Brazil | 1 | 2022 | 179 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2023 | 174 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2021 | 11 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2016 | 1001 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2015 | 204 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2020 | 11 | 0.040 |
Why?
|
| Camptothecin | 2 | 2012 | 138 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2025 | 374 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 31 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2020 | 49 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2025 | 547 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 80 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 114 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 194 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 251 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 37 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 259 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 55 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 231 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 125 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 233 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 247 | 0.040 |
Why?
|
| Goosecoid Protein | 1 | 2018 | 2 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2018 | 4 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 18 | 0.030 |
Why?
|
| Biological Mimicry | 1 | 2017 | 2 | 0.030 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 46 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 437 | 0.030 |
Why?
|
| Cell Survival | 1 | 2021 | 1100 | 0.030 |
Why?
|
| Medicare | 1 | 2023 | 903 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 51 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
|
| Glycolysis | 1 | 2019 | 340 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 39 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 121 | 0.030 |
Why?
|
| Web Browser | 1 | 2016 | 12 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 207 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1196 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 51 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 177 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 28 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 321 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 19 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 207 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 473 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 186 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 227 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 126 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 92 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 506 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 342 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 161 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 312 | 0.030 |
Why?
|
| Viruses | 1 | 2017 | 165 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 122 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 187 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 21 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 174 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 732 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 357 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1707 | 0.030 |
Why?
|
| Neoplastic Processes | 1 | 2014 | 5 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2014 | 34 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 14 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 238 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 46 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 288 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 409 | 0.030 |
Why?
|
| Pregnancy | 1 | 2007 | 7202 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 317 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 429 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 231 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1764 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 500 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 163 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 368 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 184 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 266 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 428 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2020 | 686 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 592 | 0.020 |
Why?
|
| Mass Screening | 1 | 2022 | 1360 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 24 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 90 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 487 | 0.020 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 64 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 485 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 180 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2015 | 401 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 222 | 0.020 |
Why?
|
| Mortality | 1 | 2015 | 378 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2012 | 67 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 322 | 0.020 |
Why?
|
| Washington | 1 | 2013 | 149 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 335 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 328 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 484 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 2238 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 325 | 0.020 |
Why?
|
| Amino Acids | 1 | 2015 | 519 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1454 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 286 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 22529 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 845 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 191 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 1111 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 671 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 574 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17291 | 0.020 |
Why?
|
| Machine Learning | 1 | 2015 | 587 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2865 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 222 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 674 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 306 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 100 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 403 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2105 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 555 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2046 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2406 | 0.020 |
Why?
|
| Social Support | 1 | 2010 | 646 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 523 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 777 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 1118 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2953 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 6066 | 0.010 |
Why?
|
| Child | 1 | 2015 | 22707 | 0.010 |
Why?
|